21 patents
Utility
Compositions and Methods for Autoimmunity Regulation
26 Oct 23
Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs), modified human immune cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including autoinmmune diseases.
Daniel GETTS, Robert HOFMEISTER, Patrick Alexander BAEUERLE, Dario GUTIERREZ, Dana GILMORE
Filed: 8 Jan 21
Utility
Compositions and Methods for TCR Reprogramming Using Fusion Proteins
27 Jul 23
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
Filed: 21 Dec 22
Utility
Compositions and Methods for Gamma Delta TCR Reprogramming Using Fusion Proteins
2 Mar 23
Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs), modified γδ T cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer.
Jian DING, Robert HOFMEISTER, Patrick Alexander BAEUERLE, Dario GUTIERREZ, Robert TIGHE, Julio GOMEZ RODRIGUEZ
Filed: 23 Dec 20
Utility
Compositions and Methods for Treating Cancer
2 Mar 23
Disclosed herein are methods for treatment of a mesothelin (MSLN)-expressing cancer in a human subject comprising administration of, e.g., a plurality of anti-MSLN T cell receptor fusion protein (TFP)-expressing T cells.
Alfonso QUINTÁS-CARDAMA, Robert HOFMEISTER, Robert TIGHE
Filed: 8 Apr 22
Utility
Compositions and Methods for TCR Reprogramming Using Fusion Proteins
17 Nov 22
Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs), modified human immune cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer.
Philippe KIEFFER-KWON, Ella LIBERZON, Robert HOFMEISTER, Patrick Alexander BAEUERLE, Daniel GETTS
Filed: 22 Apr 20
Utility
Compositions and Methods for TCR Reprogramming Using Fusion Proteins
3 Nov 22
Disclosed herein are dosage and administration methods for treatment of a mesothelin-expressing cancer in a human comprising administration of, e.g., a plurality of anti-mesothelin T cell receptor fusion protein-expressing T cells.
Alfonso QUINTAS-CARDAMA
Filed: 20 Mar 20
Utility
Compositions and Methods for TCR Reprogramming Using Fusion Proteins
22 Sep 22
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
Filed: 26 May 22
Utility
Compositions and methods for TCR reprogramming using fusion proteins
5 Jul 22
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
Filed: 17 Dec 18
Utility
Compositions and methods for TCR reprogramming using fusion proteins
8 Feb 22
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
Filed: 2 Aug 17
Utility
Compositions and Methods for TCR Reprogramming Using Fusion Proteins
25 Nov 21
Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs) and a TCR constant domain, modified T cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer.
Patrick Alexander BAEUERLE, Robert HOFMEISTER, Daniel GETTS, Philippe KIEFFER-KWON, Julie DONAGHEY
Filed: 8 Mar 19
Utility
Compositions and Methods for TCR Reprogramming Using Target Specific Fusion Proteins
14 Oct 21
Provided herein are T cell receptor (TCR) fusion proteins (TFPs), T cells engineered to express one or more MUC16 or IL 13Rα2 or MSLN TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Patrick Alexander Baeuerle, Robert Hofmeister, Daniel Getts, Vania Ashminova, Jian Ding
Filed: 26 Jul 19
Utility
Compositions and Methods for TCR Reprogramming Using Fusion Proteins
19 Aug 21
Provided herein are T cell receptor (TCR) fusion proteins (TFPs) having specificity for more than one tumor cell associated antigen, T cells engineered to express one or more TFP, and methods of use thereof for the treatment of diseases, including cancer.
Patrick Alexander Baeuerle, Robert Hofmeister, Jian Ding, Vania Ashminova, Michael Lofgren
Filed: 30 Aug 19
Utility
Compositions and methods for TCR reprogramming using fusion proteins
10 Aug 21
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister, Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
Filed: 10 Aug 20
Utility
CorrectedCompositions and Methods for TCR Reprogramming Using Fusion Proteins
8 Jul 21
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
Filed: 10 Jun 19
Utility
Engineered T Cells for the Treatment of Cancer
24 Jun 21
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Daniel GETTS, Ekta PATEL, Patrick BAEUERLE, Robert HOFMEISTER
Filed: 21 Dec 17
Utility
Compositions and methods for TCR reprogramming using fusion proteins
8 Jun 21
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
Filed: 10 Aug 20
Utility
Compositions and Methods for TCR Reprogramming Using Fusion Proteins
18 Mar 21
Provided herein are T cell receptor (TCR) fusion proteins (TFPs), T cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
Filed: 13 Jun 18
Utility
Compositions and Methods for TCR Reprogramming Using Fusion Proteins
18 Nov 20
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
Filed: 9 Aug 20
Utility
Compositions and Methods for TCR Reprogramming Using Fusion Proteins
18 Nov 20
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
Filed: 9 Aug 20
Utility
Compositions and Methods for TCR Reprogramming Using Fusion Proteins
1 Jul 20
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
Filed: 9 Jun 19